Haemonetics Co. (NYSE:HAE) Holdings Boosted by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P raised its position in shares of Haemonetics Co. (NYSE:HAE) by 8.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 163,856 shares of the medical instruments supplier’s stock after acquiring an additional 12,310 shares during the period. Loomis Sayles & Co. L P’s holdings in Haemonetics were worth $13,171,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Royce & Associates LP raised its position in Haemonetics by 2.6% during the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after buying an additional 30,868 shares during the period. Thrivent Financial for Lutherans grew its stake in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock valued at $88,433,000 after acquiring an additional 250,833 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Haemonetics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Haemonetics by 10.9% in the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after purchasing an additional 80,783 shares in the last quarter. Finally, Boston Trust Walden Corp boosted its holdings in shares of Haemonetics by 13.8% during the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after purchasing an additional 98,019 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $88.56 on Wednesday. The business’s 50-day simple moving average is $79.23 and its 200-day simple moving average is $82.24. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics Co. has a 52 week low of $70.25 and a 52 week high of $97.97. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 36.75, a P/E/G ratio of 1.33 and a beta of 0.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.99 earnings per share. As a group, equities research analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on HAE shares. Bank of America initiated coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research note on Friday, November 8th. BTIG Research initiated coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 target price on the stock. Finally, CL King initiated coverage on Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.